Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II, multicenter, double-blinded, randomized, 2-arm trial evaluating the
efficacy and safety of mFOLFIRINOX plus ramucirumab (Arm A) vs. mFOLFIRINOX plus placebo (Arm
B) in 94 subjects with advanced pancreatic cancer, not amenable to curative treatment. Both
arms will continue treatment until disease progression or unacceptable toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Walid Shaib, MD
Collaborators:
Eli Lilly and Company Hoosier Cancer Research Network